NSE IPO - Apply Online, Check Issue Date, Price, Lot Size & Allotment Status

Apply for NSE IPO:

Skip to main content

Live SAB Biotherapeutics, Inc. Common Stock Share Price Chart

O H L

SAB Biotherapeutics, Inc. Common Stock Performance Overview

Days Range
$3.51Low
$3.53High

Markets Today

Previous Close$3.50
Open$3.52
Volume65,269
Day's Range$3.51 - $3.53
52W Range$1.85 - $5.15
Market Cap$308.44 M

Historical Performance

1M Returns-7.65
3M Returns-12.50
6M Returns-5.41
1Y Returns+25.45
5Y ReturnsNA
10Y ReturnsNA

SAB Biotherapeutics, Inc. Common Stock Fundamentals

Market Cap$308.44 M
Dividend yield0.00
PE Ratio0.00
PEG RatioN/A
Revenue$0.00
ROE TTM0.05
EPS TTM$-0.63
Quarterly Earnings Growth YOYN/A
PB Ratio1.32
EBITDA$-45.87 M
Profit MarginN/A
Market Cap$308.44 M
Dividend yield0.00
PE Ratio0.00
PEG RatioN/A
Revenue$0.00
ROE TTM0.05
EPS TTM$-0.63
Quarterly Earnings Growth YOYN/A
PB Ratio1.32
EBITDA$-45.87 M
Profit MarginN/A

SAB Biotherapeutics, Inc. Common Stock Profit & Loss

Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Total Revenue +$0$0$0$0$0$0
Gross Profit +$0$0$0$0$0$0
Operating Income -$10.77 M-$9.73 M-$12.68 M-$15.77 M-$20.00 M-$23.38 M
EBITDA -$10.02 M-$8.98 M-$11.87 M-$15.01 M-$19.27 M-$22.56 M
Interest Expense -$69.56 K-$64.00 K-$43.29 K-$63.46 K-$62.74 K-$62.00 K
Depreciation $756.60 K$752.40 K$808.88 K$763.30 K$730.97 K$813.03 K
Income Before Tax -$5.20 M-$10.11 M$45.45 M-$16.86 M-$18.87 M-$22.49 M
Income Tax Expense $0$0$0$0$0$0
Net Income +-$5.20 M-$10.11 M$45.45 M-$16.86 M-$18.87 M-$22.49 M
Net Profit Margin ------

SAB Biotherapeutics, Inc. Common Stock Financials Balance Sheet In USD

Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Share Capital $936$936$4.76 K$5.00 K$7.58 K$8.00 K
Reserve & Surplus -$129.48 M-$139.50 M-$93.96 M-$110.71 M-$129.99 M-$153.19 M
Non-Current Liabilities $7.06 M$7.44 M$7.58 M$10.63 M$11.37 M$11.72 M
Current Liabilities $9.65 M$10.68 M$10.79 M$10.68 M$9.85 M$11.71 M
Total Liabilities $16.71 M$18.11 M$18.37 M$21.32 M$21.22 M$23.43 M
Fixed Assets $14.61 M$13.86 M$13.11 M$13.31 M$13.81 M$14.23 M
Current Assets $16.30 M$9.31 M$113.28 M$101.05 M$112.78 M$107.94 M
Total Assets $38.12 M$30.13 M$183.45 M$172.81 M$248.47 M$238.21 M

SAB Biotherapeutics, Inc. Common Stock Cash Flow

Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Net Income -$5.20 M-$10.11 M$45.45 M-$16.86 M-$18.87 M-$22.49 M
Operating Cash Flow -$7.80 M-$7.15 M-$13.05 M-$16.78 M-$14.27 M-$9.84 M
Investing Cash Flow $4.67 M$5.20 M-$129.87 M-$1.71 M-$65.65 M-$4.88 M
Financing Cash Flow -$173.99 K-$174.01 K$168.69 M-$41.69 K$89.92 M$2.36 M
Change in Cash -$3.26 M-$1.95 M$25.73 M-$18.92 M$10.02 M-$12.25 M

SAB Biotherapeutics, Inc. Common Stock Return Calculator

The SAB Biotherapeutics, Inc. Common Stock stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Returns Estimator

Based on past performance of this fund

ENTER AMOUNT
$10,000
Select Duration
5Yrs
1 Yr5 Yrs
If you had invested $10,000 5 years ago, what would its value be today?$10,000
Invested Amount$10,000
Est. Returns$0
Invest in USA Stock Today

About SAB Biotherapeutics, Inc. Common Stock

SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.

FAQs

SAB Biotherapeutics, Inc. Common Stock (SABS) share price as of September 18, 2026 is $3.53. If you are investing from India, you can always check the valuation in the INR before investing.
Yes, Indian Investors can invest in the SAB Biotherapeutics, Inc. Common Stock (SABS) Share by opening an international trading account with Angel One.
Purchasing SAB Biotherapeutics, Inc. Common Stock (SABS) share from India can be done by: Directly: By opening an international trading account with Angel One. The process would include KYC verification. The account activation takes a few minutes to a few hours, after which you can start buying SAB Biotherapeutics, Inc. Common Stock (SABS) by making deposits in US dollars. Indirectly: By investing in mutual funds and Exchange Traded Funds (ETF) that offers exposure in global stocks.
Yes, you can purchase fractional shares of SAB Biotherapeutics, Inc. Common Stock (SABS) or any other US company shares in Angel One for any dollar amount.
The market capitalization of SAB Biotherapeutics, Inc. Common Stock on September 18, 2026, is $308.44 M.
SAB Biotherapeutics, Inc. Common Stock operates in the Healthcare sector, specifically in the Healthcare industry.
In order to invest in SAB Biotherapeutics, Inc. Common Stock (SABS) you will need Proof of Identification (Aadhaar, PAN, Passport etc.) and Proof of Address (Aadhaar, Voter Card etc.). From start to end, the process is digital and can be seamless.

Diversify Your Portfolio with US Stocks

Invest in Wall Street Giants from India

+91
Top US Stocks

VIEW ALL

Open Free Demat Account!

Join our 3.8 Cr+ happy customers
+91